Recurrent Pregnancy Loss Precision Panel

Overview

• Recurrent Pregnancy Loss (RPL) is one of the most common obstetric complications, affecting more than 30% of conceptions. These can occur during preimplantation, pre–embryonic, embryonic, early fetal, late fetal and stillbirth. An important number of losses are due to genetic abnormalities, nonetheless 50% of early pregnancy losses have been associated with chromosomal abnormalities. The majority are due to de novo non–disjunctional events during meiosis and balanced paternal translocations. Traditionally, the assessment of recurrent pregnancy loss was based on karyotyping techniques. However, advances in molecular genetic technology have provided an array of information regarding genetic causes and risk factors for pregnancy loss. One of the most innovative techniques with a significant role in RPL is preimplantation genetic testing in in vitro fertilization cycles.  
• The Igenomix Recurrent Pregnancy Loss Precision Panel can be used to make a directed and accurate differential diagnosis of inability to carry out a full pregnancy ultimately leading to a better management and achieve a healthy baby at home. It provides a comprehensive analysis of the genes involved in this disease using next-generation sequencing (NGS) to fully understand the spectrum of relevant genes involved.  

Indication

• The Igenomix Recurrent Pregnancy Loss Precision Panel is indicated for those patients the following manifestations: 
  • Inability to conceive after 1 year of unprotected intercourse  
  • Family history of infertility  
  • Personal history of recurrent miscarriages 
  • Family history of recurrent miscarriages 
  • Previous failed IVF cycles 
  • Other failed assisted reproductive technology (ART) treatments 

Clinical Utility

The clinical utility of this panel is: 

• The genetic and molecular confirmation for an accurate clinical diagnosis of a symptomatic patient.  
• Early initiation of treatment with a multidisciplinary team for an initial consultation, workup and assisted reproductive technologies (ART). 
• Risk assessment of asymptomatic family members according to the mode of inheritance.

Genes & Diseases